(CercleFinance.com) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that five company-sponsored presentations will be presented at the annual meeting of the European Society of Retinal Specialists (EURETINA), which will take place will be held in Amsterdam from October 5 to 8.
Presentations will include data from two Phase 1 trials of investigational gene therapy JNJ-81201887 (JNJ-1887), a trial in patients with geographic atrophy and severe age-related macular degeneration. (AMD), as well as a trial on so-called ‘wet’ AMD.
Additionally, new research highlighting descriptive analyzes of trial populations, patient perspectives on symptoms and impact of X-linked retinitis pigmentosa (XLRP) and comorbidities in patients with of hereditary retinal dystrophy will also be shared.
“This data presented at EURETINA 2023 brings us closer to a new era of innovation in retina,” said James List, global therapeutic area head, whose team oversees a portfolio of programs, including Retina, at Janssen Research. & Development. “We are making progress in our mission to restore and preserve the vision of people living with retinal diseases,” he added.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
